Center for Scientific Review Notice of Closed Meetings, 85981 [2016-28623]
Download as PDF
<![CDATA[
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 81, No. 229 / Tuesday, November 29, 2016 / Notices
typically mice or rats that are selected
for demonstrating hallmarks of a given
disease. For cancer research, while
many mouse models exist to simulate
the response of the cancer to a particular
drug, all of the current models have
some limitations in their ability to fully
predict the concomitant physiological or
immunological response that might
result when the drug progresses to
clinical trials. This is problematic both
in models in which the cancer
spontaneously develops in the animal as
well as models in which cancerous cells
or tumors, i.e., allografts (derived from
cells of the same organism) or xenografts
(derived from cells of different
organism, usually humans), are
transplanted into an otherwise cancerfree animal.
To address these issues, researchers at
NCI developed a means of more closely
simulating in mouse models both
melanoma cancer itself and the resulting
physiological and immunological
response by creating a genetically
engineered mice (GEM)-derived allograft
(GDA). This allograft both resembles
human-like melanoma and has features
that will stimulate a normal
immunological response in the mouse.
Thus, when transplanted into a host, the
resulting tumor-containing mouse may
be used to test conventional cancer
therapies (e.g., chemotherapy and
radiotherapy), targeted drugs (e.g.,
kinase inhibitors), and
immunotherapies with an expectation
that the response in the mouse will
more closely mimic the types of
responses expected in humans if the
therapy progresses to clinical trials.
Further this melanoma-based GDA
approach may represent a new standard
for building or improving preclinical
models of other types of cancer.
Potential Commercial Applications:
• This is a novel mouse allograft
model that provides a preclinical model
of human-like advanced-stage
melanoma.
• This allograft model may be useful
for preclinical testing of conventional
therapies, targeted therapies, and
immunotherapies.
Value Proposition:
• Hgf-tg;Cdk4R24C C57BL/6 mousederived melanoma allograft with
humanized pathogenetics allows
adoption of clinically relevant
procedures and endpoints, facilitating
clinical translation.
• Features a constitutively activated
MET/MAPK pathway and disrupted
CDKN2A pathway.
• Expresses typical diagnostic
markers of human melanoma such as
DCT and TRP1.
VerDate Sep<11>2014
17:48 Nov 28, 2016
Jkt 241001
• Exhibits progression patterns
relevant to human disease.
Development Stage: Basic (Target ID).
Inventor(s): Chi-Ping Day, Glenn T.
Merlino, Zoe Weaver Ohler, Rajaa El
Meskini, Terry A. Van Dyke (all of NCI),
¨
and Thomas Tuting (University Hospital
Bonn).
Intellectual Property: HHS Reference
Number E–291–2015/0. This is a
Research Tool. Following the policy of
the National Institutes of Health, patent
protection will not be sought.
Publications:
1. Day CP, et al. ‘‘Glowing head’’ mice:
A genetic tool enabling reliable
preclinical image-based evaluation
of cancers in immunocompetent
allografts. PLoS One 2014;
9(11):e109956. [PMID 25369133]
2. Day CP, et al. Preclinical mouse
cancer models: A maze of
opportunities and challenges. Cell.
2015;163(1):39–53. [PMID
26406370]
Contact Information: Inquiries about
licensing, research collaborations, and
co-development opportunities should be
sent to John D. Hewes, Ph.D., email:
john.hewes@nih.gov.
Dated: November 22, 2016.
John D. Hewes,
Technology Transfer and Patenting
Specialist, Technology Transfer Center,
National Cancer Institute.
[FR Doc. 2016–28624 Filed 11–28–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PA–16–194:
Mentored Quantitative Research
Development Award.
Date: December 12, 2016.
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
85981
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Mark P. Rubert, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218,
MSC 7852, Bethesda, MD 20892, 301–435–
1775, rubertm@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Novel Strategies for Targeting HIV–CNS
Reservoirs without Reactivation.
Date: December 13, 2016.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Renaissance Mayflower Hotel, 1127
Connecticut Avenue NW., Washington, DC
20036.
Contact Person: Dimitrios Nikolaos
Vatakis, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 3190, Bethesda, MD 20892, 301–827–
7480.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 22, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–28623 Filed 11–28–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of meetings of the National
Center for Advancing Translational
Sciences.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
E:\FR\FM\29NON1.SGM
29NON1
]]>Agencies
[Federal Register Volume 81, Number 229 (Tuesday, November 29, 2016)]
[Notices]
[Page 85981]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-28623]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PA-16-194: Mentored Quantitative Research Development Award.
Date: December 12, 2016.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Mark P. Rubert, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5218, MSC 7852, Bethesda, MD
20892, 301-435-1775, rubertm@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR Panel: Novel Strategies for Targeting HIV-CNS Reservoirs
without Reactivation.
Date: December 13, 2016.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Renaissance Mayflower Hotel, 1127 Connecticut Avenue NW.,
Washington, DC 20036.
Contact Person: Dimitrios Nikolaos Vatakis, Ph.D., Scientific
Review Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3190, Bethesda, MD 20892, 301-
827-7480.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: November 22, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-28623 Filed 11-28-16; 8:45 am]
BILLING CODE 4140-01-P
